Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage ...

A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier ...

Allied Market Research published a report, titled, "Genomics Market by Product (Consumables and Reagent, Services, ...

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...

Clonal hematopoiesis (CH), the benign clonal expansion of hematopoietic stem cells, is often caused by somatic sequence variations in genes associated with hematologic malignancies. Over the past ...

Acting as a crucial interface, or bridge between the Van Gogh’s camera and its PC, is a BitFlow Cyton CXP4 CoaXPress 1.1 compliant quad-link frame grabber. It maintains image quality and prevents data ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

Artificial intelligence experts have warned that AI "swarms" are poised to infiltrate social media by deploying agents that mimic human behavior and exploit our tendency to follow the herd. When you ...

Collier Jennings is an entertainment journalist with a substantial amount of experience under his belt. Collier, or "CJ" to his friends and family, is a dedicated fan of genre films - particularly ...

Researchers from the Faculty of Engineering at The University of Hong Kong (HKU) have developed two innovative deep-learning algorithms, ClairS-TO and Clair3-RNA, that significantly advance genetic ...

1 Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China 2 Department of Urology of Jiangbei Campus, The First ...

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors. Under current NCCN guidelines as of mid-December 2025, ...